There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report), ...
Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Syndax Pharmaceuticals in a ...
HC Wainwright restated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a report published ...
Highlights,Target price adjustments for Syndax Pharmaceuticals reflect varied market sentiment.,Executive decisions on stock ...
About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results